Why GLP-1s Cost So Much More in the US
This page compares real, sourced prices across countries, explains the actual mechanism behind the gap, and gives an honest read on whether 2026's pricing deals changed the math - along with the real legal risk of trying to buy abroad instead.
The price gap, with real numbers
Peterson-KFF Health System Tracker (August 2023) found Ozempic's US list price of $1,028/month ran roughly 5.5 times Japan's $169, and roughly 10 times France's, Australia's, the UK's, and Sweden's price near $94. Wegovy's US list price of $1,349/month ran roughly 4 timesGermany's $328. A separate US Senate HELP Committee report (September 2024) found an even wider gap using different figures: Ozempic at $969 in the US vs. $59 in Germany - about 16 times.
These numbers are not interchangeable - each is tied to a specific drug, country, year, and whether it measures list price or an estimated net-of-rebate price. Any claim you see stating a single flat multiple without naming the comparison country and year should be treated skeptically.
Why the gap exists
RAND Corporation's 2024 international drug-pricing study found that, across 33 comparison countries, US brand-name list prices ran 4.22 times the peer-country average, and 3.22 times even after adjusting for estimated manufacturer rebates. The core structural reason: the UK's NICE, Australia's PBAC, and Canada's PMPRB all negotiate (or cap) a single national price directly with the manufacturer. The US has no equivalent single negotiator for commercial insurance - pharmacy benefit managers negotiate rebates instead, which lower the health plan's net cost but usually don't lower the list price a patient's coinsurance is calculated against.
The clearest proof the gap is about negotiating leverage, not manufacturing cost: when the US government finally got authority to negotiate a price directly - the Inflation Reduction Act's Medicare Drug Price Negotiation Program - Ozempic's negotiated Medicare price fell 71%, from $959 to $274/month, effective 2027. That lands close to several peer-country list prices cited above.
Manufacturers have not denied the gap. Novo Nordisk's CEO, testifying before the Senate HELP Committee in September 2024, pointed to PBM formulary economics rather than defending the list price directly. Eli Lilly's CEO has been more direct, saying the company "should rebalance pricing between the U.S. and Europe in terms of who's bearing the cost" of R&D - an explicit acknowledgment that US prices have been subsidizing lower prices abroad.
The 2026 update: TrumpRx and the Most-Favored-Nation deals
In November 2025, the White House announced Most-Favored-Nation pricing agreements with Novo Nordisk and Eli Lilly covering these drugs. TrumpRx.gov - a federal cash-pay portal that is not an insurance program but an aggregator linking to manufacturer discount programs - launched February 5, 2026. Reported cash prices have fallen into roughly the $150-$350/month range depending on the drug and dose (pricing is dose-selected on the live site and changes, so check trumprx.gov directly for a current figure rather than treating any single number as fixed). Separately, NovoCare's own standing self-pay price for Wegovy is $349/month, and LillyDirect's starting Zepbound price is $299/month - both well below the list prices cited above.
That said, independent analysts are skeptical the "Most Favored Nation" label means true price parity. KFF Health News (May 2026) called the deals "opaque and unenforceable" since exact terms are confidential. Forbes' health-policy coverage (June 2026) found TrumpRx prices "often aren't aligned with prices overseas" and noted overall US brand-drug list prices remain roughly 3x other wealthy nations'. Part of the narrowing is happening from the other direction too: Eli Lilly separately agreed to raise Mounjaro prices in the UK as part of the same negotiation - meaning some of the "gap closing" is Europe getting more expensive, not only America getting cheaper. Our own read: real, meaningful savings for US cash-pay patients, but not verified price parity with any single peer country.
Country by country
United Kingdom
Wegovy is available through the NHS only via a specialist weight-management service, for patients meeting strict BMI and comorbidity criteria, capped at two years of treatment. When prescribed, English patients pay the flat NHS prescription charge - £9.90 per item as of 2026/27, the same charge applied to any medicine, not a GLP-1-specific subsidy - and prescriptions are free in Scotland, Wales, and Northern Ireland. Paying privately without an NHS referral, Boots Online Doctor's own pricing (checked directly) runs £79.97/month at the lowest dose up to £205.97/month at the standard 2.4mg maintenance dose.
Canada
Wegovy has been commercially available since May 2024, historically running roughly C$450-500+/month at retail. 2026 brought a major disruption: Health Canada approved the first generic semaglutide in any G7 country (Dr. Reddy's, April 28, 2026; Apotex, May 1, 2026), after Novo Nordisk let a Canadian patent lapse over an unpaid maintenance fee. Generic semaglutide is now reported around C$88-120/month at several pharmacy chains - roughly a third of the brand price.
Australia
Ozempic is PBS-subsidized, but strictly for type 2 diabetes - not weight loss - at a A$25 general co-payment (A$7.70 concession) regardless of what the government pays the manufacturer. Wegovy is not yet PBS-listed for any indication as of this writing, though a listing was recommended in November 2025 for patients with obesity plus established cardiovascular disease specifically; private cash price runs roughly A$400-460/month at the maintenance dose. Mounjaro is also not PBS-listed - and in a notable April 2026 development, Eli Lilly itself declined to proceed with a recommended PBS listing over pricing-term disagreements, leaving an estimated 450,000 Australians with type 2 diabetes paying full private price.
Germany and Denmark
Germany's statutory health insurance generally does not reimburse these drugs for weight loss alone (only in narrow BMI-35-plus-comorbidity cases); consumer prices run roughly €172-278/month depending on dose and pharmacy. Denmark - Novo Nordisk's home market - runs a public price-comparison registry where several parallel importers compete on price for the identical product, currently showing roughly 1,280-2,300 DKK/month (about €170-310) depending on dose.
Can you just buy it abroad? The real legal picture
The FDA does have a discretionary personal-importation policy, but it is built for drugs that are not commercially available in the US for a serious condition - it generally requires no marketing of the drug to US residents, among other conditions. Since Ozempic, Wegovy, Mounjaro, and Zepbound are all FDA-approved and sold in the US, that condition does not clearly hold, and several legal sources state the policy was not designed to let people import a cheaper version of an already-approved US drug. It is enforcement discretion, not a legal entitlement - satisfying every listed condition still does not guarantee a shipment or personal supply will not be detained.
Real CBP enforcement exists - a Cincinnati DHL hub seizure of over 5,000 mis-manifested GLP-1 shipments (December 2024-March 2025) and a separate seizure of Colombia-origin Ozempic shipments worth roughly $887,000 - but both are commercial-scale smuggling operations, not documented cases of an individual traveler's personal supply being stopped. We found no reported case either way for that specific scenario.
There is also a real, separate practical risk: these are injectable biologics that must stay refrigerated and must never freeze, and a patient cannot visually tell whether a pen was ruined by a temperature excursion in transit. Combined with 2023's British Columbia crackdown on non-resident mail orders (which cut US-bound Canadian pharmacy dispensing by over 99% within six weeks) and 2026's much lower US cash-pay prices, the case for buying abroad is considerably weaker than older "medical tourism" articles suggest.
Frequently asked questions
How much more expensive is Ozempic in the US than other countries?
It depends heavily on which country and which year you compare, so treat any single "X times more" number with caution. The most-cited figures come from Peterson-KFF Health System Tracker (August 2023): US list price $936/month vs. Japan $169 (about 5.5x), and vs. France, Australia, the UK, and Sweden around $94 (about 10x). A September 2024 U.S. Senate HELP Committee report using different figures found the gap as wide as 16x against Germany ($969 vs. $59). Both are real, sourced comparisons - they simply used different countries, years, and (in the Senate report's case) estimated net-of-rebate pricing.
Why does this price gap exist?
The core mechanism, documented by RAND Corporation's 2024 international drug-pricing study, is that most peer countries negotiate a single national price directly with manufacturers (the UK's NICE, Australia's PBAC, Canada's PMPRB), while the US historically has not. In the US, pharmacy benefit managers negotiate rebates instead of a single price - those rebates lower the plan's net cost but usually do not lower the list price a patient's coinsurance is calculated against, a dynamic sometimes called the "gross-to-net bubble." The clearest proof this is about negotiating power, not manufacturing cost: when the US government did get authority to negotiate directly under the Inflation Reduction Act, Medicare's negotiated Ozempic price fell 71% (from $959 to $274/month, effective 2027) - landing close to peer-country list prices.
Did the 2025-2026 Most-Favored-Nation deals actually fix this?
Partially, and only for a specific slice of patients. In November 2025 the Trump administration announced Most-Favored-Nation pricing agreements with Novo Nordisk and Eli Lilly; the resulting TrumpRx.gov cash-pay portal launched February 5, 2026. On TrumpRx, cash-pay prices for these drugs have fallen into roughly the $150-$350/month range - a genuine, large cut from list price. But independent analysts (KFF Health News, Forbes) note the deals' terms are confidential and not independently verifiable, that self-pay savings do not count toward insurance deductibles, and that part of the "gap closing" comes from European governments agreeing to pay more (Eli Lilly raised UK Mounjaro prices as part of the same negotiation), not purely from US prices falling. The remaining gap against UK, French, Australian, or Canadian prices is still roughly 2-4x by most current estimates - not the true price parity the "Most Favored Nation" name implies.
Can I legally buy Ozempic or Wegovy from Canada or Mexico and bring it home?
This is narrower than most articles suggest. The FDA does have a discretionary "personal importation policy," but it is built for drugs that are NOT commercially available in the US for a serious condition - not for getting a cheaper version of a drug that is already FDA-approved and sold domestically. Since Ozempic, Wegovy, Mounjaro, and Zepbound are all approved and sold in the US, the policy's own conditions do not clearly cover them, and the policy is enforcement discretion, not a legal right - meeting every condition does not guarantee a shipment or personal supply will not be detained. Documented CBP enforcement (a Cincinnati DHL hub seizure of 5,000+ shipments, and a separate Colombia-origin seizure) has targeted commercial-scale smuggling, not individual travelers; we found no documented case either way for someone carrying a declared personal 1-3 month supply. Treat this as a real legal gray area, not a clear yes or no.
Is it still worth traveling to Mexico or Canada to buy it cheaper?
This calculation changed significantly in 2026. Older "medical tourism" articles compared Mexico's roughly $150-$337/month cash price against a $900-$1,350/month US list price - a large enough gap to justify a trip. With TrumpRx, NovoCare, and LillyDirect now offering US cash-pay prices in the $349-350/month range, that arbitrage has narrowed dramatically or disappeared once flights and lodging are added. Separately, the old workaround of mail-ordering from a Canadian pharmacy largely closed in 2023: after a Texas physician licensed in Nova Scotia wrote roughly 17,000 Ozempic prescriptions for American patients in three months, British Columbia restricted non-resident purchases to in-person-only, cutting US-bound dispensing by over 99% within six weeks. What is left is genuinely flying there and buying at a pharmacy counter in person - a real, but now much less lucrative, option.
Sources
- Peterson-KFF Health System Tracker, "How do prices of drugs for weight loss in the U.S. compare to peer nations' prices?" (August 17, 2023).
- U.S. Senate HELP Committee report on Ozempic/Wegovy list prices (September 24, 2024).
- RAND Corporation, "International Prescription Drug Price Comparisons" (February 2024).
- White House Fact Sheets on Most-Favored-Nation pricing (November 6, 2025) and the TrumpRx.gov launch (February 5, 2026).
- KFF Health News and Forbes independent analysis of TrumpRx pricing (May-June 2026).
- NICE Technology Appraisals TA875 (semaglutide) and TA1026 (tirzepatide); NHS England weight management guidance.
- Boots Online Doctor UK pricing (checked directly); PBS.gov.au medicine status pages.
- Health Canada generic semaglutide approval announcements (April-June 2026); British Columbia government press releases on non-resident pharmacy restrictions (2023).
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.